Arcus Biosciences (NYSE:RCUS) released its quarterly earnings results on Tuesday. The company reported ($0.64) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.40) by ($0.24), Bloomberg Earnings reports. The firm had revenue of $1.75 million for the quarter, compared to analyst estimates of $4.54 million. Arcus Biosciences had a negative net margin of 736.31% and a negative return on equity of 29.45%.
RCUS stock traded down $0.01 during mid-day trading on Friday, hitting $7.45. 8,171 shares of the company were exchanged, compared to its average volume of 111,294. The firm has a market cap of $300.61 million, a P/E ratio of -5.21 and a beta of 1.02. Arcus Biosciences has a twelve month low of $6.30 and a twelve month high of $16.06. The stock’s fifty day moving average is $8.22.
RCUS has been the subject of several recent analyst reports. ValuEngine raised shares of Arcus Biosciences from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Zacks Investment Research lowered shares of Arcus Biosciences from a “buy” rating to a “hold” rating in a report on Thursday. Svb Leerink reissued an “outperform” rating on shares of Arcus Biosciences in a report on Friday, May 3rd. Finally, Citigroup decreased their price objective on shares of Arcus Biosciences from $25.00 to $15.00 and set an “in-line” rating for the company in a report on Wednesday, June 5th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Arcus Biosciences currently has an average rating of “Buy” and an average price target of $16.56.
About Arcus Biosciences
Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. The company develops various programs targeting immuno-oncology pathways, including AB928, a dual adenosine receptor antagonist, which is in a Phase I/Ib clinical trial; and AB122, an anti-PD-1 antibody that is in Phase I clinical trial.
Featured Article: Total Return
Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.